Tremfya (guselkumab) vs Ilumya (tildrakizumab)
Tremfya (guselkumab) vs Ilumya (tildrakizumab)
Tremfya (guselkumab) and Ilumya (tildrakizumab) are both biologic medications approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tremfya works by targeting interleukin-23 (IL-23), a cytokine implicated in the inflammatory process of psoriasis, and is administered by subcutaneous injection every 8 weeks after initial dosing. Ilumya also targets IL-23, but it is administered every 12 weeks after initial doses, which may be a consideration for patients seeking less frequent dosing. Patients should consult with their healthcare provider to determine which medication is more appropriate for them based on their medical history, lifestyle, and treatment preferences.
Difference between Tremfya and Ilumya
Metric | Tremfya (guselkumab) | Ilumya (tildrakizumab) |
---|---|---|
Generic name | Guselkumab | Tildrakizumab |
Indications | Plaque psoriasis, Psoriatic arthritis | Plaque psoriasis |
Mechanism of action | IL-23 inhibitor | IL-23 inhibitor |
Brand names | Tremfya | Ilumya |
Administrative route | Subcutaneous injection | Subcutaneous injection |
Side effects | Upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, herpes simplex infections | Upper respiratory infections, injection site reactions, diarrhea, headache |
Contraindications | Known hypersensitivity to guselkumab or excipients | Known hypersensitivity to tildrakizumab or excipients |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Janssen Biotech | Sun Pharma |
Efficacy
Efficacy of Tremfya (Guselkumab) in Psoriasis
Tremfya (guselkumab) is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Guselkumab is a monoclonal antibody that selectively blocks the protein interleukin-23 (IL-23), a key driver in the pathogenesis of psoriasis. Clinical trials have demonstrated the efficacy of Tremfya in achieving significant skin clearance. In two pivotal phase III trials, VOYAGE 1 and VOYAGE 2, more than 70% of patients treated with guselkumab achieved at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 16, and these results were maintained through week 48.
Efficacy of Ilumya (Tildrakizumab) in Psoriasis
Ilumya (tildrakizumab) is another biologic agent that has been approved by the FDA for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Similar to guselkumab, tildrakizumab is a monoclonal antibody that targets IL-23. The efficacy of Ilumya was demonstrated in the reSURFACE 1 and reSURFACE 2 phase III clinical trials. These studies showed that a significant percentage of patients achieved a 75% reduction in the PASI score (PASI 75) after 12 weeks of treatment. Moreover, many patients were able to maintain these results with continued treatment at week 28.
Comparison of Efficacy in Clinical Practice
When comparing the efficacy of Tremfya and Ilumya, it is important to consider the individual patient's response and tolerance to treatment. Both medications have shown to be effective in achieving and maintaining significant skin clearance in a substantial proportion of patients with moderate to severe plaque psoriasis. The choice between these two treatments may depend on various factors, including the patient's medical history, the presence of comorbidities, and the patient's preference and lifestyle.
Long-term Efficacy and Safety
Long-term studies are essential to fully understand the efficacy and safety of new medications like Tremfya and Ilumya. Ongoing research and post-marketing surveillance continue to monitor the long-term outcomes of patients treated with these biologics. The available data suggest that both guselkumab and tildrakizumab maintain their efficacy over time, with acceptable safety profiles. However, as with any medication, it is crucial for healthcare providers to evaluate the benefits and risks of these treatments on an individual basis and monitor patients regularly for any adverse effects or loss of efficacy.
Regulatory Agency Approvals
Tremfya
Ilumya
Access Tremfya or Ilumya today
If Tremfya or Ilumya are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us